Boyer David W. 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 14, 2025
Insider Transaction Report
Form 4
Boyer David W.
Chief Corp. Affairs Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-13+1,811→ 3,809 total - Sale
Common Stock
2025-02-13$116.79/sh−955$111,538→ 2,854 total - Award
Stock Option
2025-02-12+34,153→ 34,153 totalExercise: $117.18Exp: 2035-02-12→ Common Stock (34,153 underlying) - Exercise/Conversion
Common Stock
2025-02-13+1,541→ 4,395 total - Sale
Common Stock
2025-02-13$116.69/sh−830$96,849→ 3,565 total - Award
Restricted Stock Unit
2025-02-12+6,401→ 6,401 total→ Common Stock (6,401 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−1,811→ 3,623 total→ Common Stock (1,811 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−1,541→ 4,624 total→ Common Stock (1,541 underlying)
Footnotes (9)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.87 to $117.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F6]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F7]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
- [F8]This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, and will vest as to 1,811 shares on February 13, 2026, and 1,812 shares on February 13, 2027, subject to the terms and conditions of the award.
- [F9]This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, and will vest as to 1,541 shares on February 13, 2026, 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award.